Cel-Sci, U.S. Navy extend agreement to study CEL-1000 for malaria

By Lisa Kerner

Erie, Pa., April 20 - Cel-Sci Corp. said it has extended its cooperative research and development agreement with the U.S. Naval Medical Research Center to jointly evaluate Cel-Sci's patented drug CEL-1000 against several species of malaria-causing plasmodium and as an adjuvant with various malaria vaccines.

CEL-1000, a patented small peptide, has induced protective responses against malaria, herpes simplex, viral encephalitis and cancer upon challenge in animals, according to a news release.

The drug is being tested by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, for the prevention/treatment of the avian flu virus in animal models.

Cel-Sci previously reported that CEL-1000 peptide has resulted in 100% protection against malaria (P. yoelii) infection in a mouse model after the administration of two 5 microgram doses.

Malaria, transmitted by mosquitoes, affects about 300 million to 500 million people annually and is responsible for about 2.7 million deaths each year, the company said.

Located in Vienna, Va., Cel-Sci develops immune system-based treatments for cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.